Department of Clinical Pharmacology and Toxicology, University Hospital Sveti Duh, Zagreb, Croatia.
Department of Clinical Pharmacology and Toxicology, Clinical Hospital Centre Rijeka, Rijeka, Croatia.
Pharmacol Res Perspect. 2024 Oct;12(5):e70009. doi: 10.1002/prp2.70009.
The endocannabinoid system (ECS) is a complex cell-signaling system that is responsible for maintaining homeostasis by modulating various regulatory reactions in response to internal and environmental changes. The influence of ECS on appetite regulation has been a subject of much recent research, however, the full extent of its impact remains unknown. Current evidence links human obesity to ECS activation, increased endocannabinoid levels in both central and peripheral tissues, along with cannabinoid receptor type 1 (CBR1) up-regulation. These findings imply the potential pharmacological use of the ECS in the treatment of obesity. Here, we present various pathophysiological processes in obesity involving the ECS, highlighting different pharmacological options for modulating endocannabinoid activity to treat obesity. However, the potential of those pharmacological possibilities remains under investigation and requires further research.
内源性大麻素系统(ECS)是一个复杂的细胞信号系统,通过调节各种调节反应来维持体内平衡,以响应内部和环境的变化。ECS 对食欲调节的影响是最近研究的一个主题,然而,其影响的全部范围尚不清楚。目前的证据将人类肥胖与 ECS 激活、中枢和外周组织中内源性大麻素水平升高以及大麻素受体 1(CBR1)上调联系起来。这些发现表明 ECS 有可能在肥胖症的治疗中发挥药理学作用。在这里,我们介绍了肥胖症中涉及 ECS 的各种病理生理过程,强调了调节内源性大麻素活性以治疗肥胖症的不同药理学选择。然而,这些药理学可能性的潜力仍在研究中,需要进一步研究。